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Background: We aimed to investigate the impact of Type-II Endoleak (T-II-EL) on aneurysm sac growth and reveal preoperative T-II-EL 
predictors.
methods: We enrolled 162 consecutive patients (Zenith: 61, EXCLUDER: 57, ENDURANT: 44) who underwent successful EVAR. 
Computed tomography (CT) scans before and after EVAR (1 week, 6 month, and 1 year) were reviewed to estimate T-II-EL and measure 
sac diameter. Three-dimensional volume analyses were performed during CT for measuring sac volume.Vessel number and diameter 
of the patent lumbar artery (LA) and inferior mesenteric artery (IMA) were evaluated. Variable anatomical parameters and patient 
characteristics were investigated as possible T-II-EL predictors.
results: T-II-EL was 35.8%, 15.4%, and 12.3% at 1 week, 6 months, and 1 year after EVAR, respectively. Reduction of sac diameter 
(T-II vs. non-T-II groups: −0.11 ± 3.4 mm vs. −7.3 ± 6.0 mm) and volume (T-II vs. non-T-II groups: −0.07 ± 14.6 ml vs. −24.2 ± 30.7 ml) 
significantly differed between the groups at 1 year after EVAR. Sac volume enlargement was observed in 47.6% cases in the T-II group. 
EXCLUDER use, patent LA, patent IMA, and IMA diameter were significantly associated with T-II-EL at 1 week after EVAR in univariate 
analysis. Dual antiplatelet therapy (DAPT), EXCLUDER use, number of LAs, and patent IMA were significantly associated with T-II-EL at 
1 year after EVAR. Multivariate analysis revealed that DAPT(OR:4.00 p=0.03),patent IMA(OR:12.9 p=0.02) and EXCLUDER use(OR:6.19 
p=0.001) were independent predictors of T-II-EL at 1 year after EVAR. Patent IMA was the only factor associated with sac enlargement in 
patients with persistent T-II-EL.
conclusion:  Persistent T-II-EL after EVAR was observed in 12% patients in the present stent graft system. DAPT, patent IMA and 
EXCLUDER use were independent predictors of persistent T-II-EL. Sac volume enlargement was observed in half of the patients with 
persistent T-II-EL. Because T-II-EL with patent IMA was significantly associated with sac enlargement, careful observation or additional 
intervention may be required.
